BRCA2 Variant of Uncertain Significance Before Breast Surgery
Mark, 45, has unilateral stage II, ER-positive breast cancer and a 12-gene panel showing a BRCA2 variant classified as a variant of uncertain significance. He has no family history of breast, ovarian, pancreatic, or prostate cancer. His surgeon recommends contralateral prophylactic mastectomy and risk-reducing salpingo-oophorectomy 'because of the BRCA2 result,' and schedules surgery in 6 weeks. Mark asks the counselor whether his 18-year-old daughter should be tested before his surgery. He is anxious and says he 'can't live with uncertainty.' The variant is in a splice region; the laboratory reports insufficient evidence. The counselor has the variant details and can order tumor testing or refer to a research program.
1. How should the VUS affect the surgical recommendations?
Read the worked answer
A variant of uncertain significance should not be treated as a pathogenic BRCA2 mutation. It should not by itself justify contralateral prophylactic mastectomy or risk-reducing salpingo-oophorectomy, because the risk associated with the variant is unknown and the surgeries have irreversible consequences. Mark's surgical plan should be based on his age, tumor stage and biology, family history, and accepted guidelines for average-risk or familial-risk management. The counselor should coordinate with the surgeon and medical oncologist, explain the difference between a VUS and a pathogenic variant, and correct the impression that the result confirms hereditary cancer. Tumor testing may help if it shows loss of the wild-type allele, but that is research or supportive evidence, not routine clinical proof. Referral to a research program for splicing assays or reclassification is appropriate. Document that the VUS did not drive the recommendation. If Mark still chooses contralateral surgery for other reasons, that is his decision, but the rationale should not be the VUS.
2. Should Mark's 18-year-old daughter be tested for the VUS before his surgery?
Read the worked answer
No, not for clinical management. Predictive testing for a VUS is generally not recommended because the result cannot change surveillance or risk-reducing surgery: a carrier of a VUS is managed like someone without a pathogenic finding, and a non-carrier is not reassured about hereditary risk. The daughter is 18 and legally an adult, but testing her now would create a result that is difficult to interpret and may cause anxiety without benefit. Testing relatives can sometimes be useful in research to gather segregation data, but that requires a separate consent process, not a clinical test before surgery. Explain to Mark that the priority is to clarify his own variant, not to expand testing. If the variant is later reclassified as pathogenic, the family can be recontacted and offered testing. If reclassified as benign, the daughter's risk can be revised. Document the discussion and set expectations about recontact.
3. Mark insists on the surgery and on testing his daughter. How should the counselor manage the encounter?
Read the worked answer
Acknowledge the anxiety driving the request and avoid a power struggle. State clearly that the counselor cannot order predictive testing for a VUS because it is not clinically indicated, but can help Mark make a decision about surgery that is informed. Explore what 'uncertainty' means to him: fear of recurrence, fear of passing risk to his daughter, or feeling that more surgery will buy control. Offer a second opinion from a high-risk breast clinic, a psycho-oncology referral, and a family meeting. Discuss the actual recurrence-risk data and the harms of contralateral surgery and oophorectomy. For the daughter, offer a letter explaining why testing is deferred and an appointment for her at 18 if she wants to discuss it. If Mark proceeds with surgery, ensure the consent process reflects the real reason. Document the counseling, the refusal to test the daughter, and the referrals. Maintain engagement rather than discharging him for disagreeing.